Key result
Review summarizes latest diagnosis and treatment of cancer therapy-related HF in childhood cancer survivors.
Why the study?
Pediatric cancer survivors face risks of cardiotoxicity and heart failure, which can be asymptomatic and portend worse prognosis if diagnosed late, necessitating protocols for early follow-up and treatment.
This review highlights the importance of establishing follow-up protocols for early identification and treatment of cardiotoxicity in long-term survivors of childhood cancer.
Supports routine cardiac monitoring in long-term childhood cancer survivors; leaves open optimal early intervention strategies pending prospective trials.
The improvement in survival rates in pediatric malignancies has led to an increase in the number of cancer survivors who are at risk of developing cardiotoxicity and heart failure. Cardiac dysfunction in these patients can occur asymptomatically, and the diagnosis in a symptomatic phase is associated with reduced treatment response and worse prognosis. For this reason, it is essential to establish protocols to follow up on these patients and identify those at risk of cardiotoxicity in order to start early and effective therapies. This review aims to summarize the latest findings in the diagnosis and treatment of cancer therapy-related cardiac disease in long-term survivors of childhood cancer, with a focus on heart failure.
No takes yet. Share an insight, caveat, or question.
Fernández‐Avilés et al. (2024) conducted a review in Heart failure in long-term survivors of childhood cancer. Diagnostic and therapeutic approaches was evaluated. This review summarizes the latest findings in the diagnosis and treatment of cancer therapy-related cardiac disease, focusing on heart failure in long-term survivors of childhood cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: